Predictors of BRAF Mutation in Melanocytic Nevi: Analysis Across Regions With Different UV Radiation Exposure

Background:BRAF mutations have been implicated in initiating promutagenic cellular melanocytic proliferation mostly based on homogeneous Western-based cohorts. Data addressing the possible interaction between exposure to different solar ultraviolet radiation (UVR) magnitudes and BRAF mutation rate (BMR) in melanocytic nevi are limited. Design:Extended BRAF testing for 9 mutations in 225 melanocytic nevus (MN) cases derived from 211 patients from 4 different UVR regions: Lebanon (n = 95; 110 kJ·m−2·yr−1), Syria (n = 23; 93.5 kJ·m−2·yr), Kingdom of Saudi Arabia (n = 70; 139 kJ·m−2·yr−1), and Pakistan (n = 37; 118 kJ·m−2·yr−1) was performed. Data collected included age, gender, anatomic location, and lesion size. Histological parameters recorded were MN type (junctional, compound, intradermal, classical blue, cellular blue, compound and intradermal spitz, and congenital) solar elastosis grade, and nevus pigmentation degree. Cumulative 21-year erythemally effective UV averages were derived from The National Center for Atmospheric Research. Results:BRAF mutation status was obtained in 210 cases (6.7% failed polymerase chain reaction). Overall, BMR was 62.4% (131/210) with V600E mutation accounting for 98.5% of cases. Discordant mutation status was found in 2 of 10 patients with multiple nevi. BMR differed significantly, yet nonsystematically, among UVR regions; the highest was detected in nevi coming from Syria (18/23 cases, 78%), followed by Pakistan (21/30 cases, 70%), Kingdom of Saudi Arabia (47/70 cases, 67%), and Lebanon (45/87cases, 52%). Mutation rates varied significantly across MN type (P < 0.001); the highest rate was recorded in the intradermal nevus type (33/39 cases, 84.6%), followed by the compound (26/32 cases, 81.2%) and congenital (60/74 cases 81.0%) nevi. Stratified by anatomic location, nevi occurring on the face (61/82, 74%) and trunk (58/78, 74%) had more frequent BMRs compared with those occurring on the upper (7/26, 27%) and lower extremities (5/24, 21%, P < 0.001). Severe pigmentation was less frequent in BRAF mutation–positive nevi [5/131 (4%) vs. 34/79 (43%); P < 0.001]. Multivariate independent predictors of BRAF mutation in MN were age [odds ratio (95% confidence interval ) = 1.43 (1.13–1.74) per 10 years; P = 0.004], anatomic location [P = 0.043 overall], and nevus type [P < 0.001 overall]. UVR region was not an independent predictor of BRAF mutation. Conclusions:Increased BRAF mutation with age along with the lack of a UVR magnitude–BRAF mutation association suggests that duration of exposure rather than UVR exposure dose is the more likely link to acquiring the mutation.

[1]  Q. Mi,et al.  BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han. , 2011, The Journal of investigative dermatology.

[2]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[3]  E. Simpson,et al.  Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi , 2008, Nature.

[4]  Jane Fridlyand,et al.  Improving Melanoma Classification by Integrating Genetic and Morphologic Features , 2008, PLoS medicine.

[5]  K. Flaherty,et al.  The MAPK pathway in melanoma , 2008, Current Opinion in Oncology.

[6]  L. Akslen,et al.  Mutation analysis of the EGFR–NRAS–BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma , 2008, Melanoma research.

[7]  W. Westra,et al.  Distribution of BRAF T1799A(V600E) Mutations Across Various Types of Benign Nevi: Implications for Melanocytic Tumorigenesis , 2007, The American Journal of dermatopathology.

[8]  P. Minoo,et al.  Role of BRAF‐V600E in the serrated pathway of colorectal tumourigenesis , 2007, The Journal of pathology.

[9]  M. Trivett,et al.  Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. , 2007, The Journal of investigative dermatology.

[10]  Stephen B Gruber,et al.  BRAF and NRAS mutations in melanoma and melanocytic nevi , 2006, Melanoma research.

[11]  M. Gill,et al.  B-RAF and melanocytic neoplasia. , 2005, Journal of the American Academy of Dermatology.

[12]  M. Xing,et al.  BRAF mutation in thyroid cancer. , 2005, Endocrine-related cancer.

[13]  C. Garbe,et al.  Risk factors of incident melanocytic nevi: A longitudinal study in a cohort of 1,232 young German children , 2005, International journal of cancer.

[14]  D. Tuveson,et al.  Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. , 2005, Cancer research.

[15]  L. Zon,et al.  BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma , 2005, Current Biology.

[16]  G. Saldanha,et al.  High BRAF mutation frequency does not characterize all melanocytic tumor types , 2004, International journal of cancer.

[17]  Helmut Fuchs,et al.  Effects of G-protein mutations on skin color , 2004, Nature Genetics.

[18]  Kazuhiro Takahashi,et al.  BRAF point mutations in primary melanoma show different prevalences by subtype. , 2004, The Journal of investigative dermatology.

[19]  K. Hemminki,et al.  BRAF mutations are common somatic events in melanocytic nevi. , 2004, The Journal of investigative dermatology.

[20]  Ajay N. Jain,et al.  Determinants of BRAF mutations in primary melanomas. , 2003, Journal of the National Cancer Institute.

[21]  M. Flaig,et al.  Mutations of the BRAF gene in benign and malignant melanocytic lesions. , 2003, The Journal of investigative dermatology.

[22]  I. Wistuba,et al.  BRAF Mutation: A Frequent Event in Benign, Atypical, and Malignant Melanocytic Lesions of the Skin , 2003, The American Journal of dermatopathology.

[23]  K. Smalley,et al.  A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? , 2003, International journal of cancer.

[24]  P. Ladenson,et al.  BRAF mutation in papillary thyroid carcinoma. , 2003, Journal of the National Cancer Institute.

[25]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[26]  C. Peyssonnaux,et al.  The Raf/MEK/ERK pathway: new concepts of activation , 2001, Biology of the cell.

[27]  M. Ueda,et al.  c-KIT receptor expression in cutaneous malignant melanoma and benign melanocytic naevi , 1996, Melanoma research.

[28]  R. Lew,et al.  SUNLIGHT AND CUTANEOUS MALIGNANT MELANOMA: EVIDENCE FOR AND AGAINST CAUSATION , 1990, Photochemistry and photobiology.

[29]  Daniel L. Schmoldt,et al.  UV radiation in global climate change : measurements, modeling and effects on ecosystems , 2010 .

[30]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[31]  M. Kotze,et al.  A reverse-hybridization assay for the rapid and simultaneous detection of nine HFE gene mutations. , 2000, Genetic testing.